134 related articles for article (PubMed ID: 9316006)
1. Serum CD44 levels in patients with non-small cell lung cancer and their relationship with clinicopathological features.
Takigawa N; Segawa Y; Mandai K; Takata I; Fujimoto N
Lung Cancer; 1997 Oct; 18(2):147-57. PubMed ID: 9316006
[TBL] [Abstract][Full Text] [Related]
2. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
3. ADAM28 is a serological and histochemical marker for non-small-cell lung cancers.
Kuroda H; Mochizuki S; Shimoda M; Chijiiwa M; Kamiya K; Izumi Y; Watanabe M; Horinouchi H; Kawamura M; Kobayashi K; Okada Y
Int J Cancer; 2010 Oct; 127(8):1844-56. PubMed ID: 20112342
[TBL] [Abstract][Full Text] [Related]
4. Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer.
Mizera-Nyczak E; Dyszkiewicz W; Heider KH; Zeromski J
Tumour Biol; 2001; 22(1):45-53. PubMed ID: 11054026
[TBL] [Abstract][Full Text] [Related]
5. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E
Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742
[TBL] [Abstract][Full Text] [Related]
6. Serum Human Epididymis Secretory Protein 4 (HE4) is a Potential Prognostic Biomarker in Non-Small Cell Lung Cancer.
Mo D; He F
Clin Lab; 2018 Sep; 64(9):1421-1428. PubMed ID: 30274019
[TBL] [Abstract][Full Text] [Related]
7. Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma.
Iizasa T; Fujisawa T; Saitoh Y; Hiroshima K; Ohwada H
Cancer Immunol Immunother; 1998 Aug; 46(6):345-9. PubMed ID: 9756419
[TBL] [Abstract][Full Text] [Related]
8. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
[TBL] [Abstract][Full Text] [Related]
9. High frequency expressions of CD44 standard and variant forms in non-small cell lung cancers, but not in small cell lung cancers.
Kondo K; Miyoshi T; Hino N; Shimizu E; Masuda N; Takada M; Uyama T; Monden Y
J Surg Oncol; 1998 Nov; 69(3):128-36. PubMed ID: 9846498
[TBL] [Abstract][Full Text] [Related]
10. Elastase levels in small and non-small cell lung carcinoma.
Güner G; Kirkali G; Baskin Y; Karlikaya C; Akkoçlu A
Biochem Soc Trans; 1993 Aug; 21 ( Pt 3)(3):305S. PubMed ID: 8224451
[No Abstract] [Full Text] [Related]
11. Preferential histiotypic expression of CD44-isoforms in human lung cancer.
Wimmel A; Schilli M; Kaiser U; Havemann K; Ramaswamy A; Branscheid D; Kogan E; Schuermann M
Lung Cancer; 1997 Mar; 16(2-3):151-72. PubMed ID: 9152947
[TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer.
Maeda Y; Segawa Y; Takigawa N; Takata I; Fujimoto N
Intern Med; 1996 Oct; 35(10):764-71. PubMed ID: 8933183
[TBL] [Abstract][Full Text] [Related]
13. The Clinical Research of Serum VEGF, TGF-β1, and Endostatin in Non-small Cell Lung Cancer.
Liu SG; Yuan SH; Wu HY; Liu J; Huang CS
Cell Biochem Biophys; 2015 May; 72(1):165-9. PubMed ID: 25548002
[TBL] [Abstract][Full Text] [Related]
14. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
Foss KM; Sima C; Ugolini D; Neri M; Allen KE; Weiss GJ
J Thorac Oncol; 2011 Mar; 6(3):482-8. PubMed ID: 21258252
[TBL] [Abstract][Full Text] [Related]
15. [Significance of serum neuron-specific enolase before treatment in predicting brain metastases and prognosis of advanced non-small cell lung cancer].
Chen Y; Peng W; Huang Y; Chen J; Su G; Jiang C; Xiao Y
Zhonghua Zhong Liu Za Zhi; 2015 Jul; 37(7):508-11. PubMed ID: 26463326
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of CD44 variant exon 6 expression in non-small cell lung cancer: a meta-analysis.
Zhao S; He JL; Qiu ZX; Chen NY; Luo Z; Chen BJ; Li WM
Asian Pac J Cancer Prev; 2014; 15(16):6761-6. PubMed ID: 25169522
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology.
Molina R; Augé JM; Bosch X; Escudero JM; Viñolas N; Marrades R; Ramírez J; Carcereny E; Filella X
Tumour Biol; 2009; 30(3):121-9. PubMed ID: 19506400
[TBL] [Abstract][Full Text] [Related]
18. Increased serum S-TRAIL level in newly diagnosed stage-IV lung adenocarcinoma but not squamous cell carcinoma is correlated with age and smoking.
Kargi A; Bisgin A; Yalcin AD; Kargi AB; Sahin E; Gumuslu S
Asian Pac J Cancer Prev; 2013; 14(8):4819-22. PubMed ID: 24083751
[TBL] [Abstract][Full Text] [Related]
19. An approach of selecting appropriate markers from the primary tumor to enable detection of circulating tumor cells in patients with non-small cell lung cancer.
Warawdekar UM; Sirajuddin MM; Pramesh CS; Mistry RC
J BUON; 2015; 20(3):782-90. PubMed ID: 26214631
[TBL] [Abstract][Full Text] [Related]
20. [Plasminogen activator inhibitor type 1 (PAI-1) in blood and tissue extracts of patients with non-small cell lung cancer].
Zekanowska E; Cieśliński K; Rość D
Pneumonol Alergol Pol; 2004; 72(9-10):409-14. PubMed ID: 16021996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
